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Nearly all dialysis patients receive epoetin therapy to treat
anemia. Using the United States Renal Data System, we
monitored the 14 001 patients aged 65 and older who started
dialysis and epoetin treatment in 2003–2004. We estimated
the dose–response relationship for the average epoetin dose
and hematocrit during a 3-month initiation and subsequent
3-month maintenance phase using a marginal structural
model to adjust for measured time-dependent confounding
by indication. During the initiation phase, an S-shaped
dose–response relationship for average weekly epoetin dose
and hematocrit response was found. Average hematocrit
levels rose as the epoetin dose was increased from 9000 to
approximately 22 500 units per week. At higher doses, the
effect of increasing epoetin was minimal with average
hematocrit levels plateauing at 38.5%, but this was less
evident in the maintenance phase. Among patients who
reached this phase, doses required to maintain the
hematocrit level were lower than those required to achieve
similar hematocrit levels in the initiation phase. The
dose–response curve found in our study suggests that
published recommendations for starting dose are
appropriate, and a starting dose of 7500–15 000 units per
week can maintain the hematocrit level in the desired target
range of 33–36%.
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Anemia affects nearly all end stage renal disease (ESRD)
patients, results in reduced quality of life and is associated with
decreased survival rates.1–3 In 1987, investigators reported
successful use of recombinant human erythropoietin (epoetin
or EPO, trade name EPOGEN) in treating the anemia of ESRD
patients.4–6 By 2005, nearly all dialysis patients covered by
Medicare routinely receive epoetin for treatment of anemia
associated with renal disease.7,8 Between 1991 and 2005, the
mean administered dose of epoetin increased about fourfold,
while the mean monthly hematocrit level increased from
28.5 to 36% among the ESRD population.9
The original phase I–II clinical trials demonstrated that as
epoetin dose was increased from 15 to 500 U per kg per dose,
there was a progressive increase in the achieved hematocrit
level.6 Subsequent studies examining the relationship between
epoetin dose and hematocrit (or hemoglobin) response have
primarily used administrative databases. We and others have
found that patients who receive the highest epoetin doses tend
to have low hematocrit levels.1,3,10,11 This inverse association
reflects the fact that practitioners are targeting a certain
hematocrit level, and patients who do not achieve this
level will be given higher doses. Hyporesponsive patients, who
receive the highest doses, may have underlying inflammatory
disorders that blunt the hematocrit response to epoetin.10
To estimate the true pharmacologic relationship between
epoetin dose and hematocrit response, one needs to
appropriately adjust for this confounding by indication.
Because the epoetin dose is partly determined by measured
hematocrit dosages, which are themselves affected by prior
dosing decisions, special techniques such as inverse proba-
bility weighting of marginal structural models12 are needed.
These techniques have been previously applied to studies of
vitamin D13 and parenteral iron14 use in dialysis patients as
well as to other clinical scenarios. In this paper, we use
marginal structural models to estimate the dose–response
relationship between epoetin dose and hematocrit response
in patients more than 65 years old that initiated dialysis
without having received prior epoetin therapy.
RESULT
Initiation phase
Figure 1 shows the selection process for the patients included
in the analysis. The demographics, clinical history, comor-
bidities, and facility characteristics of the 14 001 patients who
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met our eligibility criteria are shown in Table 1 overall and by
average weekly epoetin dose received in the first 3 months
after initiation of dialysis. Twenty percent of all patients had
an average weekly dose of less than 12 500 units for the first
3 months, 36% had an average weekly dose between 12 500
and 25 000 units, and 44% had an average weekly dose
greater than 25 000 units. Of the 14 001 patients, 3964 were
censored (1686 died) during the first 4 months, and 682 did
not have a hematocrit value in month 4. Figure 2 shows
the estimated relation between epoetin dose averaged over
the initiation phase and the average hematocrit level of
the population at the end of the initiation phase. As expected,
the confidence intervals are widest at each end of the
dose–response curve where there are the fewest patients in the
study population. Given that a starting dose of 13 500 units
per week resulted in an average hematocrit level of 36%,
the greatest increases in the average hematocrit level of the
population take place with epoetin doses between 9000 and
22 500 units per week. At higher doses of epoetin, the average
population hematocrit level plateaus at 38.5%.
Maintenance phase
This analysis includes the 10 208 patients who reached the
end of the initiation phase. Their characteristics are similar to
those reported for the total population in Table 1 (data not
shown), except that the mean hematocrit level (s.d.) at the
beginning of the maintenance phase was 37.0% (4.6). Figure 3
suggests that patients in the initiation phase received larger
epoetin doses compared to patients in the maintenance
phase. Of the 10 208 patients who reached the end of the
initiation phase, 2533 were censored (1262 died) during
months 4–7, and 329 did not have a hematocrit value in
month 7. The dose–response curve is shown in Figure 4a
(overall), Figure 4b (by hematocrit value achieved in month
3), and Figure 4c (by average epoetin dose administered in
the first 3 months). Compared with the initiation phase curve
(Figure 2), the overall curve in the maintenance phase (Figure
4a) is shifted to the left and has a less clear plateau. Figure 4b
indicates that the hematocrit value achieved in the initiation
phase predicts the response to epoetin in the maintenance
phase. Specifically, patients who failed to achieve an initiation
phase hematocrit level of 433% might not, on average,
achieve hematocrit levels 436% during the maintenance
phase despite very large doses of epoetin. The dose–response
curve during the maintenance phase depends on the dose
received in the initiation phase as well. Compared to patients
who received lower doses in the initiation phase, patients
who were administered higher epoetin doses in the first
3 months also tended to require higher doses in the
subsequent maintenance phase (Figure 4c).
The dose–response curves shown in Figures 2 and 4 did
not materially change when we further adjusted for profit
status (with the exception that at the lower doses, not for
profit dialysis units had higher average hematocrit values),
baseline hypertension, body mass index, glomerular filtration
rate, serum creatinine, and time-dependent iron treatment,
blood transfusions, dialysis sessions, and urea reduction
ratio; when we increased the number of knots in the cubic
spline functions for average epoetin dose; when patients with
predialysis epoetin use were included; or when we imposed
limits on very high or low inverse probability weights. The
epoetin dose necessary to maintain an average target hemato-
crit level of 33–36% in the population was 7500–15 000 U per
week. We also conducted unweighted analyses that showed
flatter dose–response curves (data not shown), a finding that
might be explained because of inappropriate adjustment for
confounding by indication.
DISCUSSION
We used longitudinal observational data to study the
hematocrit response to epoetin treatment outside of the
more controlled Phase II study setting. In the initiation phase,
we found the dose–response curve to be S-shaped, plateauing
at a population average hematocrit level of approximately
38.5% for epoetin doses greater than 20 000 units per week.
The initial starting dose ranges (based on a typical patient
weight of 70 kg) recommended by the US Food and Drug
Administration (FDA) approved labeling (11 250–22 500
37432 patients 65 years with medicare as primary payer initiated hemodialysis in 2003
35477 patients started outpatient hemodialysis within 90 days of the first ESRD service  date
30549 patients started epoetin when starting hemodialysis
19191 patients did not use predialysis epoetin
17430 patients did not have kidney transplantation and prior diagnosis of cancer or HIV
14001 pateints had predialysis hematocrit value and were not censored in the first complete month of dialysis
Figure 1 | Selection of study population from USRDS data.
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units per week),15 and the European Renal Association—
European Dialysis and Transplant Association (3750–11 250
units per week)16 are located on the steep portion of the
dose–response curve, and thus appear to be appropriate
starting doses. The National Kidney Foundation/Kidney
Dialysis Outcomes and Quality Initiative (KDOQI) guide-
lines, which used to recommend 9000–13 500 units per
week17, now recommend that ‘ythe initial ESA dose and
ESA dose adjustments should be determined by the patient’s
Hb level, target Hb level, the observed rate of increase in
Hb level, and clinical circumstances.’18
In the maintenance phase of our analysis—comprised of
those who survived the initiation phase—population average
hematocrit levels are consistently higher for the responders
(433% hematocrit level at month 3) than for the less res-
ponsive patients (o33% hematocrit level at month 3). This
finding is consistent with data from randomized controlled
trials that have shown that some patients targeted to high
hematocrit levels did not achieve the targeted levels despite
use of high epoetin dosages,19–24 indicating that high
hematocrit targets might not be achievable by some dialysis
patients. Recent clinical trials have shown that patients
targeted to higher hematocrit levels with higher epoetin doses
might have an increased mortality.24,25 As a result of these
concerns, a recent FDA black box warning advises health-care
providers to use ‘the lowest [epoetin] dose possible to
gradually increase the hemoglobin concentration’ and to
maintain the hematocrit level below 36%. In contrast to this
recommendation, in our study population, the average
epoetin dose in the initiation phase was higher than that in
the maintenance phase.
Historically, Medicare epoetin payment policy administered
by the Centers for Medicaid and Medicare Services (CMS)
was based on an upper bound of achieved hematocrit level
Table 1 | Patient and provider baseline characteristics (%) by average epoetin dose (N=14 001)
Weekly epoetin dose during initiation phase (U)a
Total o12 500 12 500 to o25 000 25 000 to o37 500 X37 500
No. of patients 14 001 2779 4991 4191 2040
Age 65 o75 years (%) 47.0 44.3 45.8 47.6 53.6
Male (%) 50.0 48.0 48.4 51.0 52.1
White race (%) 71.0 74.5 71.3 70.1 65.4
Primary diagnosis (%)
Diabetes 44.0 42.7 43.0 45.2 43.0
Hypertension 37.0 37.0 37.7 35.7 36.6
Glomerulonephritis 4.8 3.9 4.9 4.8 5.4
Cystic kidney 0.7 0.7 0.8 0.6 0.6
Cardiovascular comorbidities (%) 65.0 67.3 65.4 63.9 64.4
Non-cardiovascular comorbidities (%) 61.0 61.2 59.6 61.6 60.6
Hypertension (%) 37.0 37.0 37.7 35.7 36.6
Geographic region (%)
Northeast (Networks 1–5) 27.0 26.1 25.3 26.1 31.8
Southeast (Networks 6–8, 13, 14) 31.0 30.2 30.6 31.2 34.1
Midwest (Networks 9–12) 26.0 22.7 26.6 27.3 24.1
West (Networks 15–18) 16.0 21.1 17.6 15.4 10.00
For profit ownership (%) 77.0 74.5 75.5 80.0 81.1
Chain membership (%)
Chain 1 26.0 26.2 26.6 27.0 24.4
Chain 2 12.0 9.7 12.7 13.1 12.4
Chain 3 14.0 10.5 11.8 16.1 17.3
Chain 4 7.5 5.7 6.4 8.5 10.2
Chain 5 3.2 3.9 3.4 2.9 2.3
Small chain/non-chain (SMC/NC) 35.0 42.4 37.5 30.8 29.9
Body mass index (kg m2)b 26.7±6.5 26±6.1 26.2±6.2 27.1±6.5 28±7.1
Serum albumin (g per 100 ml)b 3.1±0.6 3.1±0.6 3.1±0.6 3.1±0.6 3.0±0.6
Serum creatinine (mg per 100 ml)b 6.0±2.8 5.7±2.7 6.0±2.8 6.1±2.8 6.5±3.1
Glomerular filtration rateb,c 10.7±4.9 11.3±5.1 10.7±4.9 10.5±4.9 10.2±4.8
Predialysis hematocrit (%) 30.1±4.9 31.5±5.2 30.4±4.9 29.5±4.6 28.8±4.5
Baseline epoetin dose per administration (U) 8497±4996 6134±4617 7019±5126 9421±2612 13 433±4993
Baseline iron use (% yes) 49.0 49.0 49.0 48.3 50.5
Notes: Plus–minus values are means±s.d.
aWeekly epoetin dose may be an average of 1–3 months, depending on length of follow-up.
bNot based on complete sample size due to missing data.
cGlomerular filtration rate is estimated value.
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without a limit on dose. CMS’ most recent policy, however,
reimburses up to a hematocrit level of 39% (which then
triggers a 25% epoetin dose reduction). Recently, the House
Ways & Means Committee (W&Ms) has held meetings
(December 2006 and June 2007) to express their concern
with overuse of epoetin and CMS’ new epoetin policy in
overreaching the upper limit of the FDA recommended target
hematocrit level (36%). Given these concerns and the results
from our analysis, an alternative Medicare policy might
be that providers first demonstrate that a dose does not result
in the desired hematocrit level before using (and being
reimbursed for) higher doses. Such a policy would promote
the use of the lowest requisite dose for patients (in our study
a starting dose of 13 500 units per week resulted in an average
hematocrit level of 36%), but it may be difficult to imple-
ment and monitor. An alternative policy would be to include
epoetin therapy costs in the ESRD composite rate payment,
which currently includes primarily the cost of dialysis and
selected laboratory tests, as suggested by the Congressional
Budget Office, the Inspector General, the Government
Accounting Office and the Medicare Payment Advisory
Committee (MedPAC).26–30 The challenge will be how to
adjust the composite rate to foster appropriate use (epoetin
dose and target hematocrit level). Our results suggest that
12 000–14 000 U per week will result in an average hematocrit
level of 36% in patients more than 65 years old within the
first 6 months of dialysis treatment. This benchmark might
be useful for calculating an epoetin adjustment to the ESRD
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Figure 4 | Dose-response curve for maintenance phase.
(a) Dose–response curve and 95% confidence intervals during
maintenance phase. (b) Dose–response curve during maintenance
phase disaggregated based on patient hematocrit level at month 3.
(c) Dose–response curve during maintenance phase disaggregated
based on epoetin dose in the first 3 months.
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composite rate, and similar analyses could be performed for
other populations.
This study has several limitations. First, a key assumption
of our analysis is that epoetin dosing decisions are based on
the hematocrit values recorded in the database, that is, that
unmeasured patient characteristics such as weight, iron
stores, malnutrition, inflammation, or epoetin responsiveness
only affect dosing decisions through their effect on the
recorded hematocrit values. Residual confounding by
unmeasured factors might underestimate the average hema-
tocrit levels for large epoetin doses (thus shifting the curve
downward as perhaps seen in the curve for nonresponders
in Figure 4b). Of note, we adjusted for the measured
confounders by inverse probability weighting; conventional
adjustment methods would not have yielded valid estimates
even in the absence of unmeasured confounding and model
misspecification. Second, our analysis is restricted to the first
6 months of dialysis treatment of Medicare patients aged 65
and older who had not received epoetin before initiation of
dialysis, and thus might not generalize to other populations.
Third, we did not have information on the route of epoetin
administration. However, we have previously reported that
more than 93% of hemodialysis patients received intravenous
administration of epoetin.31 Fourth, for the initiation phase
data, the time period of analysis might have been too short to
achieve a steady state, and this possibility is consistent with
the higher doses for similar achieved hematocrit levels
compared to the maintenance phase analysis.
In conclusion, our results suggest that doses in the range
of 7500–15 000 U per week (or 2300–4600 U given thrice
weekly) are appropriate to initiate epoetin therapy, that
similar doses will on average maintain hematocrit level in the
desired target range of 33–36%, and that hyporesponsive
patients may not be able to achieve hematocrits 436%
despite very large doses of epoetin. As reimbursement
policies for epoetin are being re-examined in the United
States, the results of our dose–response analysis might help
provide a framework for future policy.
MATERIALS AND METHODS
We estimated the effect of average epoetin dose in the first 3 months
on dialysis (initiation phase) on the achieved hematocrit level at
month 4 among incident dialysis patients who were epoetin naive.
By choosing epoetin-naive anemic patients and limiting the
observation period to the first 3 months of treatment, we selected
the period in which change in hematocrit levels would be greatest.6
The outcome was chosen at the end of the fourth month period
because a 2- to 4-week lag period has been reported for epoetin to
affect hematocrit level.32–34 To examine whether the dose–response
relationship changes after the initiation phase, we also estimated the
relationship between the average epoetin monthly dose during the
second 3-month period on dialysis (maintenance phase, months 4–6)
and the achieved hematocrit level at the end of month 7.
Study data
The United States Renal Data System (USRDS) is a national system
that includes demographic and clinical data on patients with ESRD
and their institutional providers of dialysis treatment. Medicare
covers 93% of US dialysis patients, and the USRDS Medicare claims
database includes data on monthly hematocrit levels and epoetin
doses for these patients. (The USRDS website, http://www.usrds.org,
‘Researcher’s Guide to the USRDS Database’ describes the variables,
data source, collection methods, and validation studies.) We used
the USRDS standard analytic files as of calendar years 2003 and
2004, which are the most recent available data for researchers (as of
May 2007). Institutional claims, including treatment information,
were used as the primary data set, and merged with variables from
patient, medical evidence, and facility files from the USRDS core CD
based on unique patient identifiers.
We restricted our analysis to patients who were X65 years of
age (because epoetin use before the initiation of dialysis can be
reliably determined in this group), started hemodialysis and epoetin
treatment concurrently within 90 days after their first ESRD service
date and had not used epoetin before initiation of dialysis (to ensure
we have the first epoetin claim and complete epoetin therapy infor-
mation), did not have a kidney transplant, HIV, or cancer before
starting dialysis (because these patients might respond differently to
epoetin therapy), had a predialysis hematocrit measurement, and were
not censored during the first complete month on dialysis. In the
initiation phase analysis, patients were followed until the last
hematocrit measurement in month 4 or censoring due to change of
dialysis modality, transplantation, 30 days after change of dialysis
provider, gap in outpatient dialysis services (defined as missing dialysis
treatment or hospitalization information for 30 consecutive days or
longer), or death, whichever came first. In the maintenance phase
analysis, patients were followed from month 4 to the last hematocrit
measurement in month 7 or censoring, whichever came first.
Statistical methods
For each phase (initiation and maintenance), we fit a separate
regression model to estimate the dose–response relationship between
average epoetin dose and hematocrit response. The outcome of these
models was hematocrit response at the end of follow-up (month 4
for initiation phase and month 7 for maintenance phase). The
covariates were the average epoetin dose during the follow-up
(months 1–3 for initiation phase and months 4–6 for maintenance
phase), and the following baseline variables measured at the start
of the corresponding phase: age, gender, race, primary cause of
ESRD, presence of selected comorbidities, geographic region,
chain membership, baseline epoetin, and predialysis or month 3
hematocrit levels (for initiation and maintenance phase, respec-
tively). We modeled average epoetin dose as a continuous variable.
The main features of the estimated dose–response curve were not
sensitive to the functional form used for this continuous variable as
long as enough flexibility was allowed. We used cubic splines with
five knots located at the 5th, 25th, 50th, 75th, and 95th percentiles
which, for the initiation phase, correspond to weekly epoetin doses
of 6528, 13 278, 20 005, 25 685, and 47 749 units, respectively. We
then plotted the predicted average hematocrit levels for 100 values of
epoetin dose between 500 and 50 000 units per week. Point-wise
95% confidence intervals were calculated for each estimate by using
a percentile-based nonparametric bootstrap based on 200 full
samples (with replacement) from the observed data.35 For the
maintenance phase analysis, we also estimated separate dose–
response curves by achieved hematocrit level in month 3 (o33%,
X33 to o36% and 436%).
Because, at any time, high epoetin doses are more likely to be
prescribed to patients with a low achieved hematocrit value, the
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estimates from the above regression model need to be adjusted for
this time-dependent confounding by indication. To do so, one could
naively add the post-baseline hematocrit values as covariates in the
regression model. However, because those hematocrit values are
affected by the epoetin treatment (and are on the causal pathway
between epoetin treatment and final hematocrit value), their
addition to the model would introduce bias.36 We therefore use
another method to adjust for time-dependent confounding by
indication: inverse probability weighting. That is, each patient in the
above regression models received a weight inversely proportional to
the estimated probability of having his/her own observed epoetin
dose history. Formally, under the assumption that all time-varying
predictors of both epoetin therapy and hematocrit value were
included in the analysis (as described in the next paragraph), our
weighted model estimates the parameters of a marginal structural
mean model.12,37,38 Unlike conventional methods for confounding
adjustment that add the time-dependent confounders as covariates
in the model, the weighted approach appropriately adjusts for time-
dependent confounders that are affected by prior epoetin therapy
(that is, prior hematocrit value and hospitalization),36 and mimics a
randomized trial in which subjects were assigned to different values
of average epoetin dose.
The epoetin weights were estimated by fitting two nested models:
a logistic regression model to estimate each patient’s probability of
receiving epoetin (7.3% of the patient-months had zero dose) at
each month, and a linear regression model to estimate each patient’s
density (assumed to be normal) of log epoetin dose among those
with non-zero dose at that month. Both models included baseline
demographic characteristics and medical conditions and time-
varying factors that might affect epoetin dosing. The baseline
variables were: age (years) at ESRD onset, race (black, white, or
other), gender, initial epoetin dose and number of epoetin
administrations, underlying cause of ESRD (diabetes, glomerulo-
nephritis, hypertension, cystic kidney, or other), initial hematocrit
value (predialysis for the initiation phase and in month 3 for
maintenance phase; cubic splines with five knots), presence of
cardiovascular and non-cardiovascular comorbidities,39 US geo-
graphic region (northeast, southeast, Midwest, or west), and
provider chain status (because we found a wide variation in epoetin
dosing strategies and target hematocrit values based on dialysis
chain characteristics40). The time-varying (monthly) variables were
hematocrit (in five groups:o30; 30 too33; 33 too36; 36 too39,
and 39% or greater; most recent hematocrit levels were carried
forward for 7.3% with missing hematocrit levels), hospitalization
(yes and no), and epoetin dose (cubic spline with five knots). For
ease of utility, the monthly epoetin doses found in administrative
data were divided by four to obtain approximate weekly doses. An
interaction term between hospitalization and hematocrit level was
also added because hospitalization might affect the relationship of
hematocrit response and epoetin dose.41 A patient’s epoetin weight
was computed as the inverse of the product of his/her estimated
probabilities and densities over the follow-up. Similar weights were
computed to adjust for potential selection bias due to censoring.
Both the epoetin and censoring weights were stabilized, and their
product was used to fit the weighted regression model. Analyses
were done with SAS (version 9.1).
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